Animal and experimental models
Cancer and thrombosis
Clinical trials: antiplatelet agents
Clinical trials: direct antithrombin agents
Clinical trials: fibrinolytic therapy
Clinical trials: heparins/LMWH
Clinical trials: oral anticoagulants
Diabetes and metabolic disorders
DVT and pulmonary embolism
Genetic determinants and epidemiology
Inflammation, infection and immunity
Ischaemic heart disease
New antithrombotic agents and approaches
New intravascular devices
Other thrombotic disorders and antithrombotic therapy
Polymorphism and arterial disease
TTP and HUS
Activated clotting time guided dosage optimization of a low molecular weight heparin (tinzaparin) for surgical and interventional indications
Fareed D., Iqbal O., Tobu M., Mousa S., Hoppensteadt D., Ma Q., Lietz H., Messmore H. L., Coyne E.
Application of human factor XIII in children with massive pleural effusions after open heart surgery
Schroth M., Singer H., Scharf J., Cesnjevar R., Klinge J.
Combination therapy with low-molecular weight heparin and glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: insights from the Global Registry of Acute Coronary Events (GRACE)
Agnelli G., Cannon C. P., Van De Werf F., Avezum A., Montalescot G., Lankes W., Kennelly B. M., Mazurek T., Kasper R. S., Brieger D.
Combined carrier status of prothrombin 20210 A and factor XIII-A L34 alleles as a strong risk factor for myocardial infarction: evidence of a genegene interaction
Butt C., Zheng H., Randell E., Robb D., Parfery P., Xie Y. G.
Differential effects of unfractionated heparin and a low molecular weight heparin on anti-thrombin activity during the treatment of deep vein thrombosis
Hoppensteadt D., Mayuga M., Lietz H., Florian-Kujawski M., Ahmad S., Frapaise X., Bacher P., Breddin H. K., Reid U., Fareed J.
Intracellular adhesion molecule-1 is associated with cardiovascular disease in elderly men and women
Swords Jenny N., Arnold A. M., Psaty B. M., Sharrett A. R., Kuller L. H., Fried L. P., Tracy R. P.
New diagnostic guideline for coronary heart disease in old people
Ma T., Jong G. P.
Procoagulant factors and the risk of myocardial infraction in young women
Tanis B., Helmerhorst F. M., Algra A., Van Der Graaf Y., Rosendaal F. R.
The predictive value of C-reactive protein (CRP) for myocardial infarction may be affected by aspirin therapy in men with lower extremity arterial disease
MacCallum P. K., Cooper J. A., Price C., Meade T. W.